Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer [0.03%]
晚期阴茎癌患者PD-L1、TIGIT和CD155的表达及人乳头瘤病毒状态检测
Emma Ulvskog,Peter Kirrander,Erik K Persson et al.
Emma Ulvskog et al.
Background and objective: To improve treatment for patients with penile cancer, there is a need for prognostic and treatment predictive biomarkers. The objective of this study was to examine the expression of checkpoint p...
Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence [0.03%]
新辅助免疫治疗在膀胱癌中的应用：系统综述当前证据得出的新治疗时代来临
Caio Vinicius Suartz,Richard Dobrucki de Lima,Lucas Schenk de Almeida et al.
Caio Vinicius Suartz et al.
Background and objective: Immune checkpoint inhibitors (ICIs), alone or with platinum-based chemotherapy, have increasingly been studied as neoadjuvant therapy for muscle-invasive bladder cancer (BC). We sought to evaluat...
Does Anticholinergic Burden Influence Therapeutic Success in Patients with Treatment-naïve Overactive Bladder? [0.03%]
抗胆碱能药物负担对初诊膀胱过度活动症患者治疗成功率的影响？
João Oliveira,Simão Oliveira,Luís Vale et al.
João Oliveira et al.
Background and objective: Overactive bladder (OAB) is a bothersome condition for which anticholinergic drugs remain a cornerstone treatment. However, many patients have comorbidities that require treatment with medication...
External Validation of the International Staging Collaboration for Cancer of the Prostate (STAR-CAP) Prognostic System in Patients Managed with Active Surveillance [0.03%]
国际前列腺癌分期协作委员会（STAR-CAP）预后系统在外科观察管理患者中的外部验证研究
Alejandro Berlin,Matthew Ramotar,Antonio Finelli et al.
Alejandro Berlin et al.
STAR-CAP is a system for assigning clinical prognostic groups in prostate cancer (PC). The system was developed and validated in patients with PC managed with radical treatment (rTx) with curative intent and outperforms existing systems for...
Optimizing Healthcare Resources Through Digital Perioperative Pathways: A Post Hoc Analysis of the BETTY-URO Trial [0.03%]
基于BETTY-URO试验的事后分析：通过数字化围手术期途径优化医疗资源
Alessandro Uleri,Michael Baboudjian,Gilles Pasticier et al.
Alessandro Uleri et al.
Radiomic Profiling of Tumor Thrombus for Predicting Recurrence in Renal Cell Carcinoma [0.03%]
肾细胞癌瘤栓的影像组学特征分析及其预测复发价值
Zine-Eddine Khene,Isamu Tachibana,Raj Bhanvadia et al.
Zine-Eddine Khene et al.
Background and objective: Clear cell renal cell carcinoma (ccRCC) with tumor thrombus (TT) presents a significant prognostic challenge due to its high recurrence risk. Radiomics, an imaging-based biomarker approach, has p...
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials [0.03%]
基于SORCE和ASSURE试验探讨肾脏细胞癌患者中组织学对复发率、模式及时间影响的汇总分析
Bhavna Oza,Eleni Frangou,Tim Eisen et al.
Bhavna Oza et al.
Background and objective: Outcomes after nephrectomy for intermediate- and high-risk renal cell carcinoma (RCC) according to histological subtype are poorly characterised. This study aims to determine the value of RCC his...
Nomogram for Predicting Postoperative Major Bleeding in Percutaneous Nephrolithotomy: A Retrospective Study [0.03%]
经皮肾镜取石术术后大出血预测列线图：回顾性研究
Yifan Wu,Jue Gong,Chenyu Qiu et al.
Yifan Wu et al.
Background and objective: The aim of this study was to develop a nomogram for estimating the risk of postoperative major bleeding in patients who underwent surgery for percutaneous nephrolithotomy. ...
Implementing Standardised Training and Education: The Vision of the European Association of Urology Led by the European School of Urology [0.03%]
欧洲泌尿外科协会实施标准化培训和教育：欧洲泌尿外科学院的领导愿景
Bhaskar K Somani,Carlotta Nedbal,Tiago Ribeiro de Oliveira et al.
Bhaskar K Somani et al.
Local Therapy of the Primary Tumor: An Option for Metastatic Urothelial Carcinoma in the Era of Novel Combination Therapies? [0.03%]
新型联合治疗时代的转移性尿路上皮癌局部治疗？
Renate Pichler,José Daniel Subiela,Roman Mayr et al.
Renate Pichler et al.